HYPM Inhibitors
HYPM inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of **HYPM**, a protein involved in the regulation of cellular metabolism, protein synthesis, and intracellular signaling. HYPM is believed to play a role in modulating key pathways that control energy balance, protein homeostasis, and the response to cellular stress. By inhibiting HYPM, these compounds disrupt the normal functioning of these regulatory pathways, allowing researchers to explore how changes in HYPM activity affect various aspects of cellular physiology. This inhibition provides a useful tool for studying the molecular interactions and processes that are influenced by HYPM, including its potential roles in protein synthesis, metabolic regulation, and cellular adaptation to changing environmental conditions.
The use of HYPM inhibitors in research allows scientists to investigate the broader implications of altered protein regulation and metabolic balance within cells. By blocking HYPM, researchers can observe the downstream effects on cellular processes such as energy production, protein folding, and the activation of signaling networks involved in maintaining homeostasis. This helps to reveal the underlying mechanisms by which HYPM influences cellular metabolism and stress responses, and how its inhibition leads to changes in protein function and cellular behavior. Additionally, HYPM inhibitors offer insights into the complex interplay between protein regulators and metabolic pathways, shedding light on how cells coordinate these essential functions to ensure survival and growth. Through these studies, HYPM inhibitors contribute to a deeper understanding of the molecular mechanisms governing cellular metabolism and protein regulation.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin forms a complex with FKBP12 that binds to and inhibits the mechanistic target of rapamycin (mTOR), which is a downstream effector in the PI3K/AKT pathway. HYPM is regulated through this pathway, and inhibition of mTOR leads to reduced activity of HYPM. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, AKT phosphorylation and activation are reduced, leading to decreased downstream signaling. This includes the inhibition of pathways that regulate the function and activity of HYPM. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK). By inhibiting MEK, the extracellular signal-regulated kinase (ERK) pathway is downregulated, which in turn can decrease the functional activity of HYPM that is modulated by ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Inhibition of p38 MAPK can affect the activity of transcription factors and other downstream proteins that regulate the expression and function of HYPM. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of both MEK1 and MEK2, leading to a reduction in ERK pathway signaling. This pathway is implicated in the regulation of HYPM, and thus, U0126 indirectly inhibits HYPM by decreasing its regulatory signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. It prevents the phosphorylation and activation of AKT, leading to the inhibition of downstream pathways that are responsible for the regulation of HYPM activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases are involved in multiple signaling pathways that can regulate the activity of HYPM. By inhibiting Src kinases, Dasatinib indirectly leads to the functional inhibition of HYPM. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). It prevents the phosphorylation of c-Jun and the activation of AP-1 transcription factor, which can regulate the expression and activity of HYPM, resulting in its inhibition. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an mTOR kinase inhibitor that works differently from Rapamycin by inhibiting both mTORC1 and mTORC2 complexes. This broad inhibition of mTOR signaling reduces HYPM activity through these mTOR-dependent pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of regulatory proteins that are normally degraded. This accumulation can negatively impact the pathways that regulate HYPM, leading to its inhibition. | ||||||